STRATEGIC PAPER · OPERATING MODEL

From strategy to controlled execution.

A clinical-development strategy creates value only when its logic survives translation into countries, sites, vendors, quality controls and daily decisions.

This paper defines an operating model in which MB&P owns the clinical architecture, Verum provides the execution spine and qualified local partners add depth where it changes performance.


See the operating model


Book a 20-minute Clinical Decision Diagnostic

Multiple mountain streams converge into one illuminated river, representing clinical-development functions aligned into controlled execution. WHY GOOD STRATEGIES FAIL

The fault lines are predictable.

A programme can look convincing in the boardroom and still break in execution. Most failures arise where strategic assumptions are never translated into operating rules.

01

Fragmented evidence logic

Regulatory, operational, payer and investor requirements are developed separately, producing a study that may complete but cannot carry the intended decision.

02

Optimism instead of discipline

Feasibility becomes aspiration. Country and site choices are disconnected from protocol burden and competing studies.

03

Translation gap

Endpoint and estimand logic remain in the strategy deck instead of being converted into site, patient and data-collection reality.

04

Diffuse governance

No single accountability structure catches drift while it is still inexpensive and reversible.

THE OPERATING MODEL

One strategy. One governance system. Local execution where it adds value.

The sponsor should experience one governed system, not a chain of hand-offs. Strategic order flows down. Evidence, variance and accountability flow up.

MB&P, Verum and NECTAR form one accountable operating model for controlled global execution. WHY THE MODEL IS MORE EFFICIENT

Cost efficiency comes from avoiding predictable waste.

01

Stress-test feasibility early

Commitments are locked only after country, site and patient-flow assumptions are challenged.

02

Treat start-up as strategy

Activation is governed as an evidence-critical phase, not handed off as clerical work.

03

Apply one quality logic

Standards, critical data and escalation remain consistent across partners and geographies.

04

Escalate before redesign is required

Variance is surfaced while the programme still has affordable options.

WHEN TO USE THIS MODEL

The bridge matters most when the margin for drift is smallest.

A pivotal study under time pressure

The design and initiation window does not permit iterative correction.

A viable programme is drifting

The strategy remains plausible, but recruitment, vendor, quality or governance alignment is weakening.

Geography determines value

Country and site architecture will determine access to the right patients and the credibility of execution.

Investors need proof of executability

The clinical thesis is credible; the unresolved question is whether the operating plan can withstand scrutiny.

NEXT STEP

Pressure-test the translation boundary before execution exposes it.

Bring the clinical thesis, protocol or execution plan. We will identify which assumptions have not yet been translated into executable decisions and whether the governance model can protect the intended readout. See the clinical development strategy mandate, trial rescue mandate and governance model.


Book a 20-minute Clinical Decision Diagnostic


Explore services